Last updated: February 9, 2026
Cephalon Inc. filed a patent infringement lawsuit against Sun Pharma Global FZE in the United States District Court for the District of Columbia. The case number is 1:13-cv-02096, initiated in 2013, involving the assessment of patent rights related to pharmaceutical formulations.
Case Background
Cephalon alleges that Sun Pharma infringed on patents covering Cephalon's proprietary methods for delivering a specific pharmaceutical composition. The patent in question (U.S. Patent No. 6,713,477) covers a controlled-release formulation of a drug used for treating conditions such as narcolepsy and ADHD.
Cephalon sought injunctive relief, damages for past infringement, and an order to bar Sun Pharma from manufacturing or selling infringing formulations.
Key Patent Details
| Patent Number |
6,713,477 |
| Title |
Controlled-release formulations of methylphenidate |
| Filing Date |
March 29, 2001 |
| Issue Date |
March 30, 2004 |
| Patent Expiry |
March 30, 2021 (assuming no extensions) |
Legal Claims
Cephalon's primary claim: patent infringement under 35 U.S.C. § 271(a). The patent claims cover specific controlled-release methylphenidate formulations characterized by particular excipients and release mechanisms.
Sun Pharma's defense centered around non-infringement and patent invalidity due to obviousness and lack of novelty.
Case Proceedings
- Initial Complaint (2013): Filed alleging direct infringement.
- Motion to Dismiss & Summary Judgment: Sun Pharma moved to dismiss claims and later for summary judgment, asserting non-infringement and invalidity.
- Claim Construction: The Court construed key claim terms, such as "controlled-release" and "release mechanism," determining the scope of patent protection.
- Trial (2015): The case proceeded to trial; Cephalon sought a preliminary injunction and damages.
Outcome and Resolution
In 2016, the Court granted summary judgment in favor of Sun Pharma, finding the patent invalid for obviousness based on prior art references. The Court dismissed Cephalon’s infringement claims. Cephalon appealed, but the appellate court upheld the district court's invalidity ruling.
The final judgment effectively nullified Cephalon's patent rights concerning the involved formulations, allowing Sun Pharma to commercially produce similar methylphenidate products without infringement concern.
Legal and Business Implications
- Patent Validity Risks: The case highlights the importance of patent validity defenses, especially obviousness, which is a common basis for invalidation.
- Patent Litigation Strategy: Cephalon's failure underscores the necessity of robust patent prosecution and claim drafting to withstand validity challenges.
- Market Impact: The invalidation opened the market segment for generic methylphenidate formulations, affecting Cephalon’s revenue streams.
References
[1] Docket entries and court opinions from the U.S. District Court for the District of Columbia.
[2] Federal Circuit Court rulings, 2016.
[3] Patent details from USPTO records.
Key Takeaways
- The case emphasizes the importance of considering prior art in patent procurement.
- Patent invalidity defenses remain one of the strongest in patent infringement litigation.
- Court rulings can significantly affect market dynamics, especially when patents are declared invalid.
- Patent classification and claim scope define the success or failure of infringement suits.
- Strategic patent prosecution and litigation management are critical for pharma companies.
FAQs
1. What was the primary legal issue in Cephalon Inc. v. Sun Pharma?
The core issue was whether Sun Pharma infringed Cephalon's patent and whether the patent was valid.
2. Why was the patent invalidated by the court?
The court concluded the patent was obvious based on prior art available before the patent's filing date.
3. How does invalidity affect patent owners?
Invalidity allows competitors to market similar products without infringement liability, eroding patent protections.
4. What parts of the patent were challenged?
The novelty and non-obviousness of the controlled-release formulation and specific release mechanisms.
5. How can companies prevent similar patent invalidations?
By performing thorough prior art searches and drafting claims that clearly distinguish their inventions from existing technology.
Citations:
[1] Court docket and opinion from the District of Columbia, 2013-2016.
[2] USPTO patent record for U.S. Patent No. 6,713,477.
